金喜素联合顺铂治疗晚期非小细胞肺癌32例疗效观察  

The Observation of Efficacy of the Combination of Topotecan and Cisplatin in the Treatment of 32 Patients with Advanced Non-Small Cell Lung Cancer

作　　者：孙萍 康国庆 周梦强[2] 王文胜 赵秀生 

机构地区：[1]开封市肿瘤医院内科,河南开封475003 [2]河南省肿瘤医院内一科,河南郑州450008

出　　处：《肿瘤基础与临床》2006年第3期231-232,共2页journal of basic and clinical oncology

摘　　要：目的评价金喜素与顺铂联合治疗晚期非小细胞肺癌（NscLc）的疗效及毒副反应。方法金喜素1mg/m^2静脉点滴，第1～5天；DDP25mg／m^2，静脉点滴，第1—4天；每21-28天重复为一周期，连用2个周期后评价疗效。结果CR1例，PR14例，总有效率CR＋PR46．9％。本案的主要毒副反应是骨髓抑制和胃肠道反应。结论金喜素联合顺铂治疗晚期非小细胞肺癌是一个安全、有效、经济的化疗方案，值得临床进一步研究。Objective To evaluate the efficacy and toxicity of the combination of Topotecan and Cisplatin in the treatment of patients with advanced non-small cell lung cancer. Methods Topotecan was 1 mg/m2 iv gtt on days 1 - 5. Cisplatin was 25 mg/m^2 iv gtt on days 1 - 4. The schedule was repeated 21 - 28 days, and evaluated after two cycles. Results The complete response was 1 case, and partial response was 14 cases. The overall response rate was 46.9 %. The major toxicities of this schedule were myclosuppression and gastrointestinal reactions. Conclusions Combination with Topotecan and Cisplatin is a safe, effective and economical clinical program in the treatment of patients with advanced non-small cell lung cancer, and deserves further evaluation.

关 键 词：金喜素 顺铂 化疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]